Clinical Trials
3 trialsNCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT01742286 2020-06-09
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Novartis
Phase 1 Completed
NCT02465528 2019-12-27
Ceritinib Rare Indications Study in ALK+ Tumors
Novartis
Phase 2 Terminated